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Vitiligo is a disorder of depigmentation resulting from the
destruction of melanocytes in the epidermis. The incidence of
vitiligo is 0.5–2% worldwide (Dell’anna and Picardo, 2006).
Although the exact etiology of vitiligo remains unclear, auto-
immunity is currently recognized as one of the most likely
pathogenic mechanisms (Kemp et al., 2001). Moreover, some
studies provided evidence that in vitiligo skin a signiﬁcantly
higher expression of TNF-a was detected, compared with per-
ilesional, non-lesional and healthy skin (Birol et al., 2006).
Thus, it seems that TNF-a is a key step in the development
of vitiligo (Birol et al., 2006).
Methotrexate (MTX), is an antimetabolite and antifolate
drug. Methotrexate (MTX), is an antimetabolite and antifolate
drug. It is used in the treatment of cancer, autoimmune dis-
eases, ectopic pregnancy, and for the induction of medical
abortions (Dell’anna and Picardo, 2006). It acts by inhibiting
the metabolism of folic acid. It is used as a treatment for some
autoimmune diseases including: psoriasis and psoriatic arthri-
tis, Crohn’s disease, and rheumatoid arthritis (Dell’anna and
Picardo, 2006). It has also been used for multiple sclerosis
(Dell’anna and Picardo, 2006).
It was shown in one study that methotrexate treatment
results in a decreased number of T cells capable of TNFa
production, whereas the number of T cells producing IL-10
after polyclonal activation increased (Rudwaleit et al., 2000).
Methotrexate possibly suppresses TNFa-induced NF-jB
activation (Majumdar and Aggarwal, 2001).
There is only one case report in the literature about the
effect of MTX on vitiligo. In that report, a 54-year-old female
patient with a 10-year history of rheumatoid arthritis pre-
sented with a 6 month history of rapidly progressing vitiligo
lesions over trunk and limbs. She was started on a once weekly
dose of 7.5 mg methotrexate. At three months follow up after
starting methotrexate her arthritis had improved and it wasnoticed that she had stopped developing new depigmented le-
sions, The rapid spread of depigmentation had ceased and
there was considerable repigmentation of the existing vitiligo
lesions (Sandra et al., 1998).
Methotrexate has been reported to be useful in other auto-
immune disorders like pemphigus (Lever and Goldberg, 1969).
Hence in rapidly progressing unstable vitiligo short courses of
methotrexate may help in stopping progress and bringing the
disease process under control.
Based on this, we conducted a pilot prospective study to
evaluate the effects of MTX on vitiligo. All patients signed
an informed consent and the study protocol was approved
by the local ethics committee.
Six vitiligo patients with an average age of 29 years were
recruited. Full details of patients are shown in Table 1. All
were having vitiligo involving more than 6% of the body
surface area. Pre-treatment blood tests were normal (full
blood count, biochemistry including liver function test and
chest X-ray). Liver ultrasound was done to assess baseline
liver status.
All the patients received MTX for 6 months and assessed at
0, 1, 3, 6 and 9 months. All the six patients received 25 mg dose
per week with folic acid 5 mg daily except the day on which
they took MTX. Clinical and photographic assessments re-
vealed no change in their vitiligo lesions. No patient withdrew
from the course and none of the patient discontinued the ther-
apy. The Methotrexate therapy was well tolerated and no side
effect was noted. Follow up laboratory investigations, chest X
ray and liver ultrasound were normal.
To date, we did not come across in the literature, any study
done on MTX use in vitiligo patients except the case report
mentioned above (Sandra et al., 1998).
It is true that this is a small uncontrolled pilot study and
further controlled trials are probably warranted to evaluate
the use of methotrexate in vitiligo, notwithstanding the fact
that no clinical improvement in vitiligo with the use of metho-
trexate was evident for the ﬁrst time in our study.
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Table 1 Summary of six vitiligo patients treated by Methotrexate.
Patient No. Gender Age
(years)
Duration of
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Body surface
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Accompanying
disorder
Location of
vitiligo lesion treated
Six months
post treatment outcome
1 Male 31 16 7 None Face, upper and lower extremities No change
2 Male 14 12 11 None Face, abdomen, upper and lower extremities No change
3 Male 17 2 6 None Face, back, upper and lower extremities No change
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